Current state of cardiac troponin testing in Duchenne muscular dystrophy cardiomyopathy: review and recommendations from the Parent Project Muscular Dystrophy expert panel

Open Heart. 2021 Mar;8(1):e001592. doi: 10.1136/openhrt-2021-001592.


Cardiac disease is now the leading cause of death in Duchenne muscular dystrophy (DMD). Clinical evaluations over time have demonstrated asymptomatic cardiac troponin elevations and acute elevations are associated with symptoms and cardiac dysfunction in DMD. Clinicians require a better understanding of the relationship of symptoms, troponin levels and progression of cardiac disease in DMD. As clinical trials begin to assess novel cardiac therapeutics in DMD, troponin levels in DMD are important for safety monitoring and outcome measures. The Parent Project Muscular Dystrophy convened an expert panel of cardiologists, scientists, and regulatory and industry specialists on 16 December 2019 in Silver Spring, Maryland and reviewed published and unpublished data from their institutions. The panel recommended retrospective troponin data analyses, prospective longitudinal troponin collection using high-sensitivity cardiac troponin I assays, inclusion of troponin in future clinical trial outcomes and future development of clinical guidelines for monitoring and treating troponin elevations in DMD.

Keywords: biomarkers; cardiomyopathy; dilated; genetic diseases; inborn.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Biomarkers / blood
  • Cardiomyopathies / blood*
  • Cardiomyopathies / diagnosis
  • Cardiomyopathies / etiology
  • Disease Progression
  • Echocardiography
  • Humans
  • Muscular Dystrophy, Duchenne / blood*
  • Muscular Dystrophy, Duchenne / complications
  • Parents*
  • Practice Guidelines as Topic*
  • Troponin I / blood*


  • Biomarkers
  • Troponin I